Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4 studies found for:    PULMONARY ALVEOLAR PROTEINOSIS, ACQUIRED
Show Display Options
Rank Status Study
1 Recruiting Inhalation of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Autoimmune Pulmonary Alveolar Proteinosis (PAP)
Condition: Autoimmune Pulmonary Alveolar Proteinosis
Intervention: Drug: GM-CSF
2 Not yet recruiting Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis
Condition: Autoimmune Pulmonary Alveolar Proteinosis
Intervention: Drug: Sargramostim
3 Recruiting Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Condition: Autoimmune Pulmonary Alveolar Proteinosis
Interventions: Drug: molgramostim;   Drug: placebo
4 Enrolling by invitation Whole Lung Lavage (WLL)/Inhaled Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (PAP)
Condition: Pulmonary Alveolar Proteinosis
Interventions: Drug: GM-CSF [Leukine (Sargramostim)];   Procedure: WLL

Study has passed its completion date and status has not been verified in more than two years.